A citation-based method for searching scientific literature


List of co-cited articles
865 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Histone Deacetylase Inhibitors as Anticancer Drugs.
Tomas Eckschlager, Johana Plch, Marie Stiborova, Jan Hrabeta. Int J Mol Sci 2017
616
22

HDACs and HDAC Inhibitors in Cancer Development and Therapy.
Yixuan Li, Edward Seto. Cold Spring Harb Perspect Med 2016
540
18

Erasers of histone acetylation: the histone deacetylase enzymes.
Edward Seto, Minoru Yoshida. Cold Spring Harb Perspect Biol 2014
885
13

New and emerging HDAC inhibitors for cancer treatment.
Alison C West, Ricky W Johnstone. J Clin Invest 2014
919
13


Regulation of chromatin by histone modifications.
Andrew J Bannister, Tony Kouzarides. Cell Res 2011
9

Thirty Years of HDAC Inhibitors: 2020 Insight and Hindsight.
Terence C S Ho, Alex H Y Chan, A Ganesan. J Med Chem 2020
167
9



FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma.
Bhupinder S Mann, John R Johnson, Martin H Cohen, Robert Justice, Richard Pazdur. Oncologist 2007
914
8

Anticancer activities of histone deacetylase inhibitors.
Jessica E Bolden, Melissa J Peart, Ricky W Johnstone. Nat Rev Drug Discov 2006
8

HDAC and HDAC Inhibitor: From Cancer to Cardiovascular Diseases.
Somy Yoon, Gwang Hyeon Eom. Chonnam Med J 2016
222
8

Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma.
Loredana Santo, Teru Hideshima, Andrew L Kung, Jen-Chieh Tseng, David Tamang, Min Yang, Matthew Jarpe, John H van Duzer, Ralph Mazitschek, Walter C Ogier,[...]. Blood 2012
447
7

Clinical Toxicities of Histone Deacetylase Inhibitors.
Srividya Subramanian, Susan E Bates, John J Wright, Igor Espinoza-Delgado, Richard L Piekarz. Pharmaceuticals (Basel) 2010
206
7

Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials.
Yuan Cheng, Cai He, Manni Wang, Xuelei Ma, Fei Mo, Shengyong Yang, Junhong Han, Xiawei Wei. Signal Transduct Target Ther 2019
295
7

Hallmarks of cancer: the next generation.
Douglas Hanahan, Robert A Weinberg. Cell 2011
7

BET bromodomain inhibition as a therapeutic strategy to target c-Myc.
Jake E Delmore, Ghayas C Issa, Madeleine E Lemieux, Peter B Rahl, Junwei Shi, Hannah M Jacobs, Efstathios Kastritis, Timothy Gilpatrick, Ronald M Paranal, Jun Qi,[...]. Cell 2011
6

Selective inhibition of BET bromodomains.
Panagis Filippakopoulos, Jun Qi, Sarah Picaud, Yao Shen, William B Smith, Oleg Fedorov, Elizabeth M Morse, Tracey Keates, Tyler T Hickman, Ildiko Felletar,[...]. Nature 2010
6

The role of histone deacetylases (HDACs) in human cancer.
Santiago Ropero, Manel Esteller. Mol Oncol 2007
650
6

Cancer epigenetics: from mechanism to therapy.
Mark A Dawson, Tony Kouzarides. Cell 2012
6


Epigenetics in cancer.
Shikhar Sharma, Theresa K Kelly, Peter A Jones. Carcinogenesis 2010
6

Histone Modifications and Cancer.
James E Audia, Robert M Campbell. Cold Spring Harb Perspect Biol 2016
357
6

Histone deacetylases (HDACs): characterization of the classical HDAC family.
Annemieke J M de Ruijter, Albert H van Gennip, Huib N Caron, Stephan Kemp, AndrĂ© B P van Kuilenburg. Biochem J 2003
6


Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
Freddie Bray, Jacques Ferlay, Isabelle Soerjomataram, Rebecca L Siegel, Lindsey A Torre, Ahmedin Jemal. CA Cancer J Clin 2018
6

Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.
Hyuna Sung, Jacques Ferlay, Rebecca L Siegel, Mathieu Laversanne, Isabelle Soerjomataram, Ahmedin Jemal, Freddie Bray. CA Cancer J Clin 2021
6

Advances and Challenges of HDAC Inhibitors in Cancer Therapeutics.
Jesse J McClure, Xiaoyang Li, C James Chou. Adv Cancer Res 2018
149
6


Functions of bromodomain-containing proteins and their roles in homeostasis and cancer.
Takao Fujisawa, Panagis Filippakopoulos. Nat Rev Mol Cell Biol 2017
294
5

Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors.
Cliona Grant, Fahd Rahman, Richard Piekarz, Cody Peer, Robin Frye, Robert W Robey, Erin R Gardner, William D Figg, Susan E Bates. Expert Rev Anticancer Ther 2010
170
5



Recent Progress in Histone Deacetylase Inhibitors as Anticancer Agents.
Loredana Cappellacci, Diego R Perinelli, Filippo Maggi, Mario Grifantini, Riccardo Petrelli. Curr Med Chem 2020
44
11


Functions and mechanisms of non-histone protein acetylation.
Takeo Narita, Brian T Weinert, Chunaram Choudhary. Nat Rev Mol Cell Biol 2019
395
5

Histone Deacetylases (HDACs): Evolution, Specificity, Role in Transcriptional Complexes, and Pharmacological Actionability.
Giorgio Milazzo, Daniele Mercatelli, Giulia Di Muzio, Luca Triboli, Piergiuseppe De Rosa, Giovanni Perini, Federico M Giorgi. Genes (Basel) 2020
87
5

HDAC inhibition potentiates immunotherapy in triple negative breast cancer.
Manuela Terranova-Barberio, Scott Thomas, Niwa Ali, Nela Pawlowska, Jeenah Park, Gregor Krings, Michael D Rosenblum, Alfredo Budillon, Pamela N Munster. Oncotarget 2017
95
5

Development of the first small molecule histone deacetylase 6 (HDAC6) degraders.
Ka Yang, Yanling Song, Haibo Xie, Hao Wu, Yi-Ting Wu, Eric D Leisten, Weiping Tang. Bioorg Med Chem Lett 2018
98
5

Zinc binding groups for histone deacetylase inhibitors.
Lei Zhang, Jian Zhang, Qixiao Jiang, Li Zhang, Weiguo Song. J Enzyme Inhib Med Chem 2018
97
5

Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents.
Madhusoodanan Mottamal, Shilong Zheng, Tien L Huang, Guangdi Wang. Molecules 2015
442
5

HDAC6 is a microtubule-associated deacetylase.
Charlotte Hubbert, Amaris Guardiola, Rong Shao, Yoshiharu Kawaguchi, Akihiro Ito, Andrew Nixon, Minoru Yoshida, Xiao-Fan Wang, Tso-Pang Yao. Nature 2002
5

Next-generation of selective histone deacetylase inhibitors.
Feifei Yang, Na Zhao, Di Ge, Yihua Chen. RSC Adv 2019
21
23

Histone deacetylases: a saga of perturbed acetylation homeostasis in cancer.
Sabnam Parbin, Swayamsiddha Kar, Arunima Shilpi, Dipta Sengupta, Moonmoon Deb, Sandip Kumar Rath, Samir Kumar Patra. J Histochem Cytochem 2014
87
4


Zinc-dependent Deacetylase (HDAC) Inhibitors with Different Zinc Binding Groups.
Yan Li, Fang Wang, Xiaoxue Chen, Jie Wang, Yonglong Zhao, Yongjun Li, Bin He. Curr Top Med Chem 2019
35
11

Histone deacetylases and cancer.
Bruna Barneda-Zahonero, Maribel Parra. Mol Oncol 2012
306
4

FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases.
Ryohei Furumai, Akihisa Matsuyama, Nobuyuki Kobashi, Kun-Hyung Lee, Makoto Nishiyama, Hidenori Nakajima, Akito Tanaka, Yasuhiko Komatsu, Norikazu Nishino, Minoru Yoshida,[...]. Cancer Res 2002
579
4

Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation.
Stephen J Haggarty, Kathryn M Koeller, Jason C Wong, Christina M Grozinger, Stuart L Schreiber. Proc Natl Acad Sci U S A 2003
829
4

Dysregulated Class I histone deacetylases are indicators of poor prognosis in multiple myeloma.
Sridurga Mithraprabhu, Anna Kalff, Annie Chow, Tiffany Khong, Andrew Spencer. Epigenetics 2014
101
4


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.